Clinical curative effect observation of terlipressin in patients with cirrhosis and refractory ascites

Abstract

Objective To study the clinical curative effect of terlipressin in patients with cirrhosis and refractory ascites. Methods 62 patients with cirrhosis and refractory ascites in our hospital from March 2012 to August 2014 were selected as the object of study, randomly divided into observation group and control group, 31 cases in each group. Observation group was treated with terlipressin, control group received liver protection and other conventional treatment. Compared clinical curative effect, changes of vital signs, portal vein diameter, spleen vein diameter, depth of ascites, adverse reactions of two groups. Results The total effective rate of observation group was 83.9%, significantly higher than 61.3% of control group (P<0.05). After treatment, 24 h urine volume of observation group was (1148.76±19.35)ml, significantly higher than (1069.48±17.51)ml of control group (P<0.05). After treatment, body weight, abdominal circumference, portal vein diameter, spleen vein diameter, depth of ascites of observation group were (61.76±4.16)kg, (90.32±3.58)cm, (11.27±1.35)mm, (7.58±0.96)mm, (41.19±17.22)mm, significantly lower than (65.35±6.71)kg, (98.16±3.27)cm, (12.48±0.69)mm, (9.23±1.18)mm, (53.86±16.63)mm of control group (P<0.05). There were 1 case of slight abdominal pain, 2 cases of increased stool frequency in observation group during the treatment, above adverse symptoms were lighter, all alleviated by oneself. Conclusion Terlipressin in the treatment of liver cirrhosis with refractory ascites can effectively reduce portal vein diameter, spleen vein diameter, ascites, improve the liver function of patients, with obvious curative effect, safe and reliable, worthy of clinical application and promotion. Key words: Liver cirrhosis; Refractory ascites; Terlipressin